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Purpose
The generation of T lymphocytes with specific reactivity
against autologous tumor cells is a prerequisite for effec-
tive targeted cellular therapies. We established a proto-
col for tumor infiltrating lymphocytes (TILs) cultures
from small biopsies or surgically resected material
obtained from patients with pancreatic ductal adenocar-
cinoma (PDAC) and patients with glioblastoma.
Methods
Tumor specimens obtained from 17 patients with PDAC
and 16 patients with glioma were cultured with TIL
medium, containing IL-2, IL-15 and IL-21. Activity of
TILs directed against shared tumor associated antigens
(TAAs, mesothelin, survivin and NY-ESO-1, EGFRvIII)
was detected by Intracellular staining (ICS). Cytotoxicity
was measured using a Chromium-51 release assay and
the specific activity of TILs against autologous tumor
was measured by INF-g production. TCRVb analysis was
investigated by a multiplex antibody TCR Vb specific
panel. TCR clonality was gauged by CDR3 region PCR
analysis and subsequent sequencing. The T cell pheno-
type, as well as activation/exhaustion marker profile was
tested by flow cytometry.
Results
We could reliably expand TILs, that resided predomi-
nantly in the central memory population (CD45RA-,
CCR7+), from 33/33 patients. We were able to expand
about 1.5 x 10e9 TIL from small PDAC biopsies. TIL
showed reactivity to common TAAs, i.e. to mesothelin
(16/17 in PDAC, 8/16 in glioma), survivin (12/17 in
PDAC, 6/16 in glioma) or to NY-ESO-1(11/17 in
PDAC, 6/16 in glioma) defined by intracellular cytokine
staining. TIL cultures exhibited preferential usage of Vb
families (e.g. some TIL showed 99.3% Vb13.2, 99.60%
Vb2, 97.00% Vb5.1 in CD4+ or CD8+ TIL). A PDAC
Vb13.2+, CD8+ TIL clone strongly recognized autolo-
gous tumor cells, defined by INF-g production, which
could be blocked by the anti-HLA class 1 antibody
(W6/32). TIL from glioma patients exhibited up to 25%
IFN-g and TNF-a production directed against autolo-
gous tumor cells, defined by ICS. TILs from PDAC and
glioma showed strong cytolytic functions directed
against autologous tumor cells, i.e. up to 70% specific
lysis at an effector/target ratio at 25/1 by chromium-51
release assay.
Conclusions
We have optimized methods for generating pancreatic
cancer and glioblastoma specific TIL cultures from
small resected tumor specimens. Tumor specimens are
currently sequenced to detect potential targets for anti-
PDAC and anti-glioma directed T cell clones. A Phase
I study to administer TIL for patients with pancreatic
cancer or glioblastoma will start at Karolinska.
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